TY - JOUR
T1 - European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders
AU - Al-Toma, Abdulbaqi
AU - Volta, Umberto
AU - Auricchio, Renata
AU - Castillejo, Gemma
AU - Sanders, David S.
AU - Cellier, Christophe
AU - Mulder, Chris J.
AU - Lundin, Knut E. A.
N1 - Funding Information:
1Department of Gastroenterology, St. Antonius Hospital, Nieuwegein, The Netherlands 2Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy 3Department of Translational Medical Science, Section of Paediatrics, University of Naples, Naples, Italy 4Department of Paediatric Gastroenterology, Hospital Universitari Sant Joan de Reus, Universitat Rovira I Virgili, IISPV, Reus, Spain 5Gastroenterology and Liver Unit, Royal Hallamshire Hospital & University of Sheffield, Sheffield, UK 6Gastroenterology Department, Hôpital Européen Georges Pompidou, Paris, France 7Department of Gastroenterology, VU Medical Centre, Amsterdam, The Netherlands 8Department of Gastroenterology, Oslo University Hospital Rikshospitalet, Oslo, Norway 9KG Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway *Board representatives nominated by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).
Publisher Copyright:
© Author(s) 2019.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - This guideline presents recommendations for the management of coeliac disease (CD) and other gluten-related disorders both in adults and children. There has been a substantial increase in the prevalence of CD over the last 50 years and many patients remain undiagnosed. Diagnostic testing, including serology and biopsy, should be performed on a gluten-containing diet. The diagnosis of CD is based on a combination of clinical, serological and histopathological data. In a group of children the diagnosis may be made without biopsy if strict criteria are available. The treatment for CD is primarily a gluten-free diet (GFD), which requires significant patient education, motivation and follow-up. Slow-responsiveness occurs frequently, particularly in those diagnosed in adulthood. Persistent or recurring symptoms necessitate a review of the original diagnosis, exclude alternative diagnoses, confirm dietary adherence (dietary review and serology) and follow-up biopsy. In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline also deals with other gluten-related disorders, such as dermatitis herpetiformis, which is a cutaneous manifestation of CD characterized by granular IgA deposits in the dermal papillae. The skin lesions clear with gluten withdrawal. Also, less well-defined conditions such as non-coeliac gluten sensitivity (NCGS) and gluten-sensitive neurological manifestations, such as ataxia, have been addressed. Newer therapeutic modalities for CD are being studied in clinical trials but are not yet approved for use in practice.
AB - This guideline presents recommendations for the management of coeliac disease (CD) and other gluten-related disorders both in adults and children. There has been a substantial increase in the prevalence of CD over the last 50 years and many patients remain undiagnosed. Diagnostic testing, including serology and biopsy, should be performed on a gluten-containing diet. The diagnosis of CD is based on a combination of clinical, serological and histopathological data. In a group of children the diagnosis may be made without biopsy if strict criteria are available. The treatment for CD is primarily a gluten-free diet (GFD), which requires significant patient education, motivation and follow-up. Slow-responsiveness occurs frequently, particularly in those diagnosed in adulthood. Persistent or recurring symptoms necessitate a review of the original diagnosis, exclude alternative diagnoses, confirm dietary adherence (dietary review and serology) and follow-up biopsy. In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline also deals with other gluten-related disorders, such as dermatitis herpetiformis, which is a cutaneous manifestation of CD characterized by granular IgA deposits in the dermal papillae. The skin lesions clear with gluten withdrawal. Also, less well-defined conditions such as non-coeliac gluten sensitivity (NCGS) and gluten-sensitive neurological manifestations, such as ataxia, have been addressed. Newer therapeutic modalities for CD are being studied in clinical trials but are not yet approved for use in practice.
KW - Coeliac disease
KW - coeliac neuropathy
KW - dermatitis herpetiformis
KW - enteropathy associated T-cell lymphoma
KW - gluten ataxia
KW - neurocoeliac
KW - non-coeliac gluten sensitivity
KW - refractory coeliac disease
KW - seronegative coeliac disease
KW - slow-responder coeliac
UR - https://www.scopus.com/pages/publications/85064572800
U2 - 10.1177/2050640619844125
DO - 10.1177/2050640619844125
M3 - Review article
C2 - 31210940
SN - 2050-6406
VL - 7
SP - 583
EP - 613
JO - United European gastroenterology journal
JF - United European gastroenterology journal
IS - 5
ER -